Related Experiment Video

Updated: Jul 21, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?

F Sánchez1, J Mensa, J A Martínez

  • 1Institut Clínic d'Infeccions i Immunologia, Hospital Clínic i Provincial de Barcelona, 08026 Barcelona, Spain. MI0001@imas.imim.es

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 15, 2003
PubMed

Insights

For elderly patients with community-acquired pneumonia (CAP), a 3-day azithromycin course combined with ceftriaxone showed better outcomes than a 10-day clarithromycin course. This combination therapy may reduce hospital stays and mortality rates.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Community-acquired pneumonia (CAP) poses significant risks for elderly patients.
  • Combination antibiotic therapy, specifically beta-lactam plus macrolide, is a common treatment approach for CAP.
  • The choice of macrolide may influence treatment outcomes in this patient population.

Purpose of the Study:

  • To compare the efficacy and safety of ceftriaxone plus a 3-day course of azithromycin versus ceftriaxone plus a 10-day course of clarithromycin in elderly patients with CAP.
  • To evaluate differences in prognosis, mortality rates, and length of hospital stay between the two macrolide treatment arms.

Main Methods:

  • An open-label, prospective study was conducted involving 896 assessable elderly patients with CAP.
  • Patients were randomized to receive either ceftriaxone with a 3-day azithromycin course or ceftriaxone with a 10-day clarithromycin course.
  • Outcomes assessed included Pneumonia Patient Outcomes Research Team (PORT) severity score, incidence of bacteremia, length of hospital stay, and mortality rate.

Main Results:

  • No significant differences were observed in CAP severity scores or bacteremia incidence between the azithromycin and clarithromycin groups.
  • Patients treated with azithromycin experienced a significantly shorter hospital stay (7.4 days vs. 9.4 days; P<.01).
  • The mortality rate was significantly lower in the azithromycin group (3.6% vs. 7.2%; P<.05) compared to the clarithromycin group.

Conclusions:

  • The choice of macrolide antibiotic in combination therapy for elderly CAP patients may impact treatment outcomes.
  • A shorter 3-day course of azithromycin, when combined with ceftriaxone, appears to be associated with improved clinical outcomes, including reduced hospital stay and mortality.
  • Shorter antibiotic courses, such as with azithromycin, may enhance patient compliance with therapy.

More Related Videos

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...